Importancia de la tiroglobulina sérica preablativa en la predicción de sobrevida libre de enfermedad en cáncer diferenciado de tiroides

Díaz, R.; Véliz, Jesús; Wohllk, Nelson

doi:10.4067/s0034-98872013001200002

Cited by 2 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…El corte en temporalidad elegido se sustenta en el hecho que en nuestro centro se solicita pTg en el primer control post operatorio. Pese a que la vida media de la Tg sérica presenta un rango que varía entre uno a seis días 5 , llegando a su nadir en un período de 3 a 4 semanas posterior a la cirugía 6 , vemos cómo podría utilizarse también los valores precoces, que, en algunos casos podría ayudar a tomar una conducta en forma más precoz.…”

Section: Discussionunclassified

See 1 more Smart Citation

Análisis de tiroglobulina preablativa y cáncer diferenciado de tiroides preoperatorio

et al. 2022

View full text Add to dashboard Cite

Analysis of pre-ablative and preoperative thyroglobulin in differentiated thyroid cancerBackground: The measurement of plasma thyroglobulin (Tg) is widely used in the monitoring of differentiated thyroid cancer (CDT). In recent years, its value as a prognostic marker prior to ablation with radioiodine has increased, demonstrating its high negative predictive value. Recent studies indicate that a wide variety of factors could potentially influence pre-ablative Tg values, including residual tumor burden and stimulation modality. Aim: To relate the value of pre-ablative Tg with the amount of preoperative disease burden, lymph node metastases, treatment, and presence of residual disease. Material and Methods: Retrospective observational study of 70 patients with CDT treated between 2012 and 2018. The amount of disease burden was defined as the sum of largest diameter of individual tumors in each patient, and as the individually largest tumor per patient and number of metastatic lymph nodes. Results: A smaller tumor size and absence of remnant tissue was associated with lower Tg values, although the association was not always significant. Furthermore, no significant difference was found between Tg levels measured within or more than 14 days after the surgical procedure. Thus, an early measurement of pTg after surgery would allow an initial therapeutic decision making. Conclusions: A statistical association between pre-ablative Tg levels and the amount of preoperative tumor tissue burden was found in some subgroups of patients.

show abstract

Section: Discussionunclassified

“…La Tg corresponde a un precursor proteico de las hormonas tiroideas, ubicado únicamente en la glándula tiroides. La vida media de la Tg sérica presenta un rango que varía entre uno a seis días 5 , llegando a su nadir en un período de 3 a 4 semanas posterior a la cirugía 6 .…”

unclassified

Análisis de tiroglobulina preablativa y cáncer diferenciado de tiroides preoperatorio

et al. 2022

View full text Add to dashboard Cite

show abstract

The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer

Wang

et al. 2020

J. Cancer

View full text Add to dashboard Cite

Objective: To investigate the correlation between the BRAF V600E gene mutation and clinicopathological features and thyroid function after iodine-131 treatment in patients with papillary thyroid cancer (PTC). Methods: A total of 128 PTC patients who underwent iodine-131 treatment after a total thyroidectomy from February 2015 to November 2016 at Hunan Cancer Hospital, China, were recruited. There were 25 males and 103 females. The age range was 11 to 73 years old. The BRAF V600E mutation in tumor tissues was detected by amplification-restriction mutation system polymerase chain reaction (ARMS-PCR), and the serum levels of Tg, TSH, Tg-Ab, and Tpo-Ab were measured by chemiluminescence after iodine-131 treatment. The BRAF V600E mutation was shown to be associated with clinicopathological characteristics and thyroid function indicators after iodine-131 treatment. Results: BRAF V600E mutation was detected in 75 of the 128 patients (58.6%) and was observed more frequently in cases with elevated Tg levels (Tg>1.00) at 3, 6, 12, and 18 months after treatment compared with patients without any BRAF mutations (P<0.05). Patients with BRAF V600E mutation had significant lower level of Tg-Ab at 3 and 12 months after treatment with iodine-131 than patients without BRAF V600E mutation (P<0.05). Among the 75 BRAF V600E patients, no significant association was found between the levels of TSH and Tpo-Ab after iodine-131 treatment (P>0.05). The BRAF V600E mutation was closely associated with the high-risk and age of the patient (≥45 years old) (P<0.05), but there was no significant correlation with gender, clinical stage, and distant metastasis. Conclusion:The BRAF V600E mutation is closely related to serum Tg elevation after treatment with iodine-131 in papillary thyroid cancer. These findings suggest that this BRAF mutation may be a predictor of the efficacy of iodine-131 treatment for papillary thyroid cancer.

show abstract

Importancia de la tiroglobulina sérica preablativa en la predicción de sobrevida libre de enfermedad en cáncer diferenciado de tiroides

Cited by 2 publications

References 17 publications

Análisis de tiroglobulina preablativa y cáncer diferenciado de tiroides preoperatorio

Análisis de tiroglobulina preablativa y cáncer diferenciado de tiroides preoperatorio

The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer

Contact Info

Product

Resources

About